RT Journal Article SR Electronic T1 Survival analysis of hospital length of stay of novel coronavirus (COVID-19) pneumonia patients in Sichuan, China JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.04.07.20057299 DO 10.1101/2020.04.07.20057299 A1 Wang, Zhuo A1 Ji, John S. A1 Liu, Yang A1 Liu, Runyou A1 Zha, Yuxin A1 Chang, Xiaoyu A1 Zhang, Lun A1 Liu, Qian A1 Zhang, Yu A1 Zeng, Jing A1 Dong, Ting A1 Xu, Xinyin A1 Zhou, Lijun A1 He, Jun A1 Deng, Yin A1 Zhong, Bo A1 Wu, Xianping YR 2020 UL http://medrxiv.org/content/early/2020/04/10/2020.04.07.20057299.abstract AB Objective Allocation of medical resource is essential to a strong public health system in response to COVID-19. Analysis of confirmed COVID-19 patients’ hospital length of stay in Sichuan can be informative to decision-making in other regions of the world.Design A retrospective cross-sectional study.Data and Method Data from confirmed COVID-19 cases in Sichuan Province were obtained from the National Notifiable Diseases Reporting System (NNDRS) and field survey. We collected information on demographic, epidemiological, clinical characteristics, and the length of hospital stay for confirmed patients. We conducted an exploratory analysis using adjusted multivariate cox-proportional models.Participants A total of 538 confirmed patients of COVID-19 infection in Sichuan Province from January to March 2020.Outcome measure The length of hospital stay after admissions for confirmed patients.Results From January 16, 2020 to March 4, 2020, 538 human cases of COVID-19 infection were laboratory-confirmed, and were hospitalized for treatment. Among these, 271 (50%) were 45 years of age or above, 285 (53%) were male, 450 (84%) were considered as having mild symptoms. The median hospital length of stay was 19 days (interquartile range (IQR): 14-23, Range: 3-41). Adjusted multivariate analysis showed that longer hospital length of stay was associated with factors aged 45 and over (HR: 0.74, 95% CI: 0.60-0.91), those admitted to provincial hospital (HR: 0.73, 95% CI: 0.54-0.99), and those with serious illness (HR: 0.66, 95% CI: 0.48-0.90); living in areas with more than 5.5 healthcare workers per 1000 population (HR: 1.32, 95% CI: 1.05-1.65) was associated with shorter hospital length of stay. There was no gender difference.Conclusions Preparation control measures of COVID-19 should involve the allocation of sufficient medical resources, especially in areas with older vulnerable populations and in areas that lack basic medical resources.Strengths and limitations of this study▸ Patients at least 45 years, those with serious illness, those living in areas with fewer healthcare workers per 1,000 people, and those admitted to higher levels of hospitalization had longer lengths of hospitalization, while gender, time interval from onset to visit the hospital had no effect on the length of the hospital stay.▸ Preparation of timely evidence-based prevention and control measures for COVID-19 involve allocation of sufficient medical resources, especially in areas with older vulnerable populations and in areas that lack basic medical resources.▸ Based on findings, it is of great significance to strengthen the construction of multi-level medical institutions in response to public health emergencies and occupation of medical resources.▸ The characteristics of inpatients can be further subdivided to obtain more detailed inpatient characteristics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Grants from Science and Technology Bureau of Sichuan province (COVID-19 science and technology emergency project, No. 2020YFS0015) and Sichuan Provincial Leading Group Office for Talent Work (Sichuan provincial “Tianfu ten thousand talents plan” fund in 2018).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support our study are available from Sichuan CDC but restrictions apply to the availability of these data.